Clinical trial
Dasatinib in Relapsed Chronic Lymphocytic Leukemia
NCT00438854 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00438854 |
|---|---|
| Title | Dasatinib in Relapsed Chronic Lymphocytic Leukemia |
| Official title | Phase II Study of Dasatinib (BMS-354825) in Relapsed Chronic Lymphocytic Leukemia |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Brigham and Women's Hospital Dana-Farber Cancer Institute Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Dasatinib |
| Enrollment | 15 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Mar 1, 2013 |
| First posted | Feb 22, 2007 |
| Last update posted | Dec 13, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: